Vident Investment Advisory LLC Increases Stake in Myriad Genetics (MYGN)

Vident Investment Advisory LLC lifted its holdings in shares of Myriad Genetics (NASDAQ:MYGN) by 6.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 115,121 shares of the company’s stock after acquiring an additional 7,029 shares during the period. Vident Investment Advisory LLC owned approximately 0.16% of Myriad Genetics worth $3,954,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Prudential Financial Inc. raised its stake in Myriad Genetics by 3.9% in the 3rd quarter. Prudential Financial Inc. now owns 131,073 shares of the company’s stock valued at $4,742,000 after purchasing an additional 4,900 shares during the last quarter. State of Wisconsin Investment Board grew its holdings in Myriad Genetics by 38.7% in the 4th quarter. State of Wisconsin Investment Board now owns 63,800 shares of the company’s stock valued at $2,191,000 after buying an additional 17,800 shares in the last quarter. Chartwell Investment Partners LLC grew its holdings in Myriad Genetics by 31.4% in the 4th quarter. Chartwell Investment Partners LLC now owns 120,546 shares of the company’s stock valued at $4,140,000 after buying an additional 28,831 shares in the last quarter. Swiss National Bank grew its holdings in Myriad Genetics by 3.4% in the 4th quarter. Swiss National Bank now owns 118,500 shares of the company’s stock valued at $4,070,000 after buying an additional 3,900 shares in the last quarter. Finally, CS Mckee LP grew its holdings in Myriad Genetics by 42.2% in the 3rd quarter. CS Mckee LP now owns 42,650 shares of the company’s stock valued at $1,543,000 after buying an additional 12,650 shares in the last quarter.

How to Become a New Pot Stock Millionaire

MYGN stock traded down $1.43 during midday trading on Friday, hitting $28.00. 877,916 shares of the stock were exchanged, compared to its average volume of 714,849. The stock has a market cap of $1,955.80, a PE ratio of 26.67, a P/E/G ratio of 1.97 and a beta of 0.52. Myriad Genetics has a fifty-two week low of $17.50 and a fifty-two week high of $41.57. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.81 and a current ratio of 2.05.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.07. The company had revenue of $194.00 million during the quarter, compared to analysts’ expectations of $188.72 million. Myriad Genetics had a return on equity of 9.59% and a net margin of 16.67%. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 earnings per share. equities research analysts predict that Myriad Genetics will post 1.15 earnings per share for the current year.

In other Myriad Genetics news, VP Richard M. Marsh sold 13,759 shares of the business’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $36.25, for a total transaction of $498,763.75. Following the completion of the sale, the vice president now owns 136,385 shares of the company’s stock, valued at $4,943,956.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Richard M. Marsh sold 37,654 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $40.25, for a total value of $1,515,573.50. Following the sale, the vice president now directly owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,533 shares of company stock valued at $2,133,272. 6.70% of the stock is owned by company insiders.

MYGN has been the subject of several analyst reports. ValuEngine upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. BidaskClub lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 28th. BTIG Research initiated coverage on Myriad Genetics in a research note on Friday, January 5th. They set a “buy” rating and a $41.00 target price on the stock. Stephens set a $45.00 price target on Myriad Genetics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, Barclays increased their price target on Myriad Genetics from $30.00 to $35.00 and gave the company an “equal weight” rating in a research report on Monday, January 22nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $30.75.

WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/vident-investment-advisory-llc-boosts-stake-in-myriad-genetics-inc-mygn.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply